Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.
The company's President and CEO, Marc H. Hedrick, M.D., will engage in a fireside chat with H.C. Wainwright's VP of Equity Research, Sean Lee. The discussion will be available on demand starting September 5, 2025, at 7:00 AM ET for registered conference attendees.
Details
News Market Reaction – PSTV
On Sep 3, the first trading day after this news, PSTV closed 7.60% above the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright. The fireside chat will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting with Dr. Hedrick and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.